ArticleMolecular cancer therapeutics2014
Natural compound Alternol induces oxidative stress-dependent apoptotic cell death preferentially in prostate cancer cells.
Article in Molecular cancer therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Alternol-Induced Oxidative Modification of SQSTM1/p62 Is Associated with Nrf2 Signaling and Autophagy-Related Responses in Prostate Cancer Cells.Antioxidants (Basel, Switzerland) · 2026Article
- Alternol inhibits GAPDH activity and disrupts glycolytic flux preferentially in cancer cells.Frontiers in pharmacology · 2026Article
- Sideroflexin family genes were dysregulated and associated with tumor progression in prostate cancers.Human genomics · 2025Article
- Natural compound Alternol exerts a broad anti-cancer spectrum and a superior therapeutic safety indexFrontiers in pharmacology · 2024Article
- Natural compound Alternol actives multiple endoplasmic reticulum stress-responding pathways contributing to cell death.Frontiers in pharmacology · 2024Article
- The Apoptotic and Anti-Warburg Effects of Brassinin in PC-3 Cells via Reactive Oxygen Species Production and the Inhibition of the c-Myc, SIRT1, and β-Catenin Signaling Axis.International journal of molecular sciences · 2023Article
- Anticancer effect and apoptosis induction by azaflavanone derivative in human prostate cancer cells.Apoptosis : an international journal on programmed cell death · 2022Article
- Alternol triggers immunogenic cell deathOncoimmunology · 2021Article
- Alternol Sensitizes Renal Carcinoma Cells to TRAIL-Induced Apoptosis.Frontiers in pharmacology · 2021Article
- Alternol/Alteronol: Potent Anti-cancer Compounds With Multiple Mechanistic Actions.Frontiers in oncology · 2020Review
- Natural compound Alternol as a novel therapeutic for prostate cancer treatment.American journal of clinical and experimental urology · 2020Review
- Xanthine oxidase-mediated oxidative stress promotes cancer cell-specific apoptosis.Free radical biology & medicine · 2019Article
- Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer.The Prostate · 2019Article
- ADP-Ribose and oxidative stress activate TRPM8 channel in prostate cancer and kidney cells.Scientific reports · 2019Article
- Inhibition of human prostate cancer (PC-3) cells and targeting of PC-3-derived prostate cancer stem cells with koenimbin, a natural dietary compound fromDrug design, development and therapy · 2018Article
- Article
- Growth inhibition and apoptosis induction by alternol in pancreatic carcinoma cells.World journal of gastroenterology · 2015Article
- Hypoxia-Targeted Drug Q6 Induces G2-M Arrest and Apoptosis via Poisoning Topoisomerase II under Hypoxia.PloS one · 2015Article
- Scaffold protein MAPK8IP2 expression is a robust prognostic factor in prostate cancer associated with AR signaling activity.Asian journal of andrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
Prostate cancers at the late stage of castration resistance are not responding well to most of current therapies available in clinic, reflecting a desperate need of novel treatment for this life-threatening disease. In this study, we evaluated the anticancer effect of a recently isolated natural compound, Alternol, in multiple prostate cancer cell lines with the properties of advanced prostate cancers in comparison to prostate-derived nonmalignant cells. As assessed by trypan blue exclusion assay, significant cell death was observed in all prostate cancer cell lines except DU145 but not in nonmalignant (RWPE-1 and BPH1) cells. Further analyses revealed that Alternol-induced cell death was an apoptotic response in a dose- and time-dependent manner, as evidenced by the appearance of apoptosis hallmarks such as caspase-3 processing and PARP cleavage. Interestingly, Alternol-induced cell death was completely abolished by reactive oxygen species scavengers N-acetylcysteine and dihydrolipoic acid. We also demonstrated that the proapoptotic Bax protein was activated after Alternol treatment and was critical for Alternol-induced apoptosis. Animal xenograft experiments in nude mice showed that Alternol treatment largely suppressed tumor growth of PC-3 xenografts but not Bax-null DU-145 xenografts in vivo. These data suggest that Alternol might serve as a novel anticancer agent for patients with late-stage prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.